Europe PMC

Background The emergence of new treatments has significantly elevated treatment expectations for psoriasis. However, existing Korean severity definitions and treatment targets of psoriasis remain primarily centered on traditional Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) thresholds, often underestimating the disease burden in high-impact special areas.Objective To develop a revised Korean expert consensus on psoriasis severity and treatment targets that incorporate the

Objectives Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.Methods Pregnancies to women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) and inflammatory bowel disease (IBD) were identified within

Background People with psoriasis are at increased risk for nonmelanoma skin cancers (NMSC) and melanoma. Conventional immunosuppressants and TNF-α inhibitors may further increase skin malignancies, while the risks associated with other biologics are less clear. This study aimed to determine skin malignancy risks in psoriasis patients treated with cyclosporine, methotrexate, TNF-α inhibitors, IL-12/23, IL-17, and IL-23 inhibitors.Methods Using the TriNetX database, psoriasis patients without skin

Background Primary cutaneous T-lymphomas (CTCL), particularly in their early stages, frequently present with clinical and histopathologic features that overlap with atopic dermatitis (AD) and psoriasis, contributing to diagnostic delay and ineffective, or even deleterious, treatment approaches. Thus, minimally invasive molecular tests capable of distinguishing CTCL from benign inflammatory dermatoses are urgently needed.Objectives To determine whether tape strip transcriptomics can detect diseas

Background Deucravacitinib, an oral tyrosine kinase 2 inhibitor, has demonstrated efficacy and safety in clinical trials; however, real-world evidence remains limited.Objective To evaluate real-world effectiveness, safety, and treatment persistence of deucravacitinib in Korean patients with plaque psoriasis.Methods This retrospective multicenter study included adults with plaque psoriasis treated with deucravacitinib at 3 tertiary hospitals. Efficacy was assessed using Psoriasis Area and Severit

Background Psoriasis is a chronic disease with a multidimensional impact that extends beyond skin symptoms, affecting physical, emotional, social well-being and satisfaction with care. This study aims to explore the perceived self-reported impact of psoriasis on patients' well-being across different life stages and to identify risk and protective factors associated with well-being over time.Methods A cross-sectional observational study was conducted using an electronic questionnaire administered

During the phase III trial (NCT04839016), the outbreak of coronavirus disease 2019 (COVID-19) inevitably caused vunakizumab interruption in patients with psoriasis. This study extracted the data from Huashan Hospital, where almost all patients experienced drug interruption, and aimed to explore the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis and the impact of treatment interruption. A total of 90 patients with moderate-to-severe plaque psoriasis receiv

Background Psoriasis is a chronic immune‑mediated inflammatory skin disease that is strongly associated with metabolic dysregulation and excess adiposity. Dietary strategies that reduce energy intake either by continuous daily caloric restriction (CCR) or time‑limited/periodic intake such as intermittent fasting (IF) or ketogenic diets (Keto) may improve psoriasis severity through weight loss, metabolic improvements, alterations in gut microbiota, and immune-metabolic effects.Objective We aimed

Psoriatic arthritis is increasingly recognized as a systemic inflammatory disease with multiple comorbidities, yet the full spectrum of dental complications associated with psoriatic arthritis has not been clearly defined. This nationwide population based cohort study evaluated whether patients with psoriatic arthritis are at elevated risk of diverse dental diseases. Using a nationwide population-based health insurance database, we identified 40,920 newly diagnosed psoriatic arthritis cases and

Background Biologics targeting key cytokines have enabled near-complete clearance in psoriasis treatment. As 90% reduction in the Psoriasis Area and Severity Index (PASI90) emerges as a meaningful goal of treatment, maintaining PASI90 without flare-up has become important.Objective To identify factors associated with PASI90 maintenance for ≥1 year without flare-up and predictors of drug discontinuation.Methods This multicenter retrospective cohort study included moderate-to-severe plaque psorias

Psoriatic arthritis is a chronically progressive, inflammatory disease mediated by immunity, accompanied by severe disability, which seriously affects the patient's physical and mental health. Despite considerable advances in the treatment of psoriatic arthritis, there remains a subset of patients for whom none of the available treatments is effective. Consequently, we identified novel drug targets for psoriatic arthritis by integrating adaptive immune-related genes. We combined Mendelian random

Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin-36 receptor inhibitors in 2022. However, contemporary real-world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized. Using a Japanese hospital-based insurance claims database (Medical Data Vision Co. Ltd.), we conducted a retrospective cohort study for patients with these psoriasis subtypes who initiate

No abstract supplied.Weiterlesen

BackgroundIncreasing evidence shows that, compared with the general population, the prevalence of coronavirus disease 2019 is significantly higher in patients with psoriasis treated with immunosuppressive therapy. However, the underlying mechanisms have not yet been clarified.Materials and methodsThe aim of this study was to further investigate the molecular mechanisms underlying these two diseases. Gene expression profiles for coronavirus disease 2019 and psoriasis were downloaded from the gene

Vitamin D (VD) is a secosteroid hormone with critical physiologic roles in calcium homeostasis and bone mineralization. Recently, studies have uncovered VD's broader effects on immune system and nervous system function. VD receptors (VDRs) and enzymes responsible for the metabolism of VD have been discovered in dorsal root ganglion (DRG) neurons and nociceptive sensory neurons, implicating VD as a potential regulator of neurogenic inflammation. Neurogenic inflammation is a phenomenon in which se

Background Difficult-to-treat psoriatic arthritis (D2T PsA) represents a challenging condition characterized by inadequate response to multiple therapeutic agents. Real-world data on the effectiveness of Janus kinase inhibitors (JAKi) in this population remain limited.Objective To evaluate the effectiveness, safety, and treatment persistence of Upadacitinib (UPA) in patients with D2T PsA using both clinical and ultrasound assessments.Patients and methods This observational retrospective study in

Psoriasis is an immune-mediated chronic inflammatory skin disease characterized by scaly plaques, erythema, and thick skin. Psoriasis management is complicated and multifaceted as this disease is linked to serious systemic consequences like infections, psoriatic arthritis, cardiovascular diseases, and psychological complications. In the current study, a mice model of psoriasis was established by topical application of 5% imiquimod (IMQ) cream on the shaved dorsal skin and left ear pinna of mice

Introduction The global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Despite the existence of a diverse array of therapeutic interventions, approximately 40-50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.Areas covered This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-1

Background Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.Objectives To evaluate the efficacy and safety of socrodeucitinib in patients with moderate-to-severe plaque psoriasis.Methods In this phase 2, double-blind, placebo-controlled trial, 125 patients were randomly assigned (1

Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of primary MACE in psoriasis patients receiving biological therapies, stratified by biological class, compared with biologic-naïve psoriasis patients. Whethe

Objectives We aimed to determine whether the short-term response to biologics in biologic-naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course.Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET) group if they started biologic therapy within 2 years of PsA diagnosis, otherwise they were considered in the delayed treatment (DT) group. The p

Introduction Psoriasis, a chronic immune-mediated inflammatory skin condition with systemic implications and substantial psychosocial burden, affects individuals across races and ethnicities. This study explored social drivers of health (SDOH), disease burden, and the impact of psoriasis across races and ethnicities.Methods An online, cross-sectional survey was conducted among adult US patients with psoriasis (September-December 2023). Participants were recruited through the National Psoriasis F

Introduction The therapeutic landscape of moderate-to-severe plaque psoriasis has been transformed by interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors, which offer superior effectiveness compared to older biologics. However, a substantial proportion of patients experience primary or secondary treatment failure, necessitating a therapeutic switching.Areas covered This review integrates real-world evidence from studies identified through a PubMed search for publications on sequencing a

Interleukin (IL)-17 and IL-23 inhibitors have transformed psoriasis care, delivering high clearance rates and quality-of-life gains. Nevertheless, inadequate response or adverse events can lead to treatment discontinuation or biologic switching. Dose modifications are also commonly implemented in routine practice to optimize efficacy, safety, and cost. The objective of this study is to characterize real-world outcomes of dose adjustment and switching of IL-17 and IL-23 inhibitors in Thai patient

IL-17 and TNF blockade effectively treats hidradenitis suppurativa and psoriasis, yet the relative importance of the different cell types that respond to IL-17 and TNF remains unresolved. Keratinocytes are viewed as the dominant effector cells, whereas fibroblasts have recently emerged as important contributors. In mice, topical imiquimod induces IL-17- and TNF-dependent skin inflammation and models psoriasis. Here, we demonstrate that intradermal injection of IL-17 and TNF elicits inflammation